In this webinar, learn about optimizing pre-clinical drug development by decoding genetic information stored in the adaptive immune system’s T-cell and B-cell receptors.
Attendees will learn about the basics of immune receptor profiling, as well as how immunosequencing can be applied to advance drug discovery and develop targeted therapies. The featured speaker will discuss how to use immunosequencing in pre-clinical mouse models to identify biomarkers and prioritize drug candidates.
Join Patrick Raber, Ph.D., Director, Immune Medicine at Adaptive Biotechnologies, for the live webinar on Thursday, November 10, 2022, at 1 p.m. Eastern/10 a.m. Pacific.
For Research Use Only. Not for use in diagnostic procedures.
Patrick Raber, PhD, Director, Immune Medicine, Adaptive Biotechnologies
Patrick Raber, Ph.D., is an immunologist with more than 12 years of research experience and an expert in the field of immunosequencing. His current role as Director, Immune Medicine at Adaptive is focused on incorporating immunosequencing into translational research and clinical trials for Adaptive’s biopharmaceutical and academic partners. He specializes in experimental design, data analysis and data interpretation.
Who Should Attend?
- Biopharma professionals involved in pre-clinical discovery
- Translational research scientists
- Early-stage pharmaceutical or biotechnology companies
- Anyone engaged in early drug development
What You Will Learn
In this webinar you will learn:
- The basics of immune receptor profiling
- How to use immunosequencing in pre-clinical mouse models
- How immunosequencing can be applied to inform drug discovery and development
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision, and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable diagnosis, monitoring, and treatment for diseases such as cancer, autoimmune disorders and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.